Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
The company will initially develop a vaccine to tackle colorectal and pancreatic cancers
Read More
Author: Esme Needham
IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
Perovial is the first ever hyaluronic acid injectable treatment to be licensed for acute Peyronie’s disease
Read More
En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
The US sees around 476,000 new Lyme cases every year
Read More
ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
Anaphylaxis is the most serious type of allergic reaction and occurs more commonly in boys
Read More
Otsuka Pharmaceutical’s Dawnzera receives EC approval for hereditary angioedema prevention
Dawnzera showed an 81% reduction in the four-weekly rate of HAE attacks compared to placebo
Read More- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
